Literature DB >> 9060544

Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system.

A C Buzaid1, M I Ross, C M Balch, S Soong, W H McCarthy, L Tinoco, P Mansfield, J E Lee, A Bedikian, O Eton, C Plager, N Papadopoulos, S S Legha, R S Benjamin.   

Abstract

PURPOSE: To critically review the accuracy of the current American Joint Committee on Cancer (AJCC) staging system for cutaneous melanoma and propose a more useful staging system.
METHODS: Retrospective evaluation of the published data as well as a reanalysis of the University of Alabama and Sydney Melanoma Unit (UAB/SMU) data bases (n = 4,568) for patients with primary melanoma was performed to examine specifically the impact of level of invasion and ulceration on the prognostic value of tumor thickness. In addition, an overlay graphic technique was used to compare the Kaplan-Meier survival curves of patients with local recurrences, satellites, in-transit metastases, and nodal metastases reported in the literature.
RESULTS: Tumor thickness and ulceration remained the most powerful prognostic indicators in patients with stage I and II disease. Level of invasion provided statistically significant prognostic information only in the subgroup of patients with tumor thickness < or = 1 mm, but the absolute 10-year survival differences were small and inconsistent (level II, 95%; level III, 85%; level IV, 89%). The best statistical fit for tumor thickness cutoffs was at 1 versus 2 versus 4 mm. The overlay graphic technique showed that patients who developed satellite lesions or local recurrence had prognoses similar to those of patients with stage III disease. The most important prognostic factor for patients with nodal metastases was number of involved nodes rather than size.
CONCLUSION: Our analysis showed that the current AJCC staging system has many inaccuracies that should be modified to conform to published data. On the basis of our analysis and review of the literature, we propose a new and more accurate staging system.

Entities:  

Mesh:

Year:  1997        PMID: 9060544     DOI: 10.1200/JCO.1997.15.3.1039

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  28 in total

Review 1.  Reducing primary melanoma mortality.

Authors:  E C Borden
Journal:  Curr Oncol Rep       Date:  2000-07       Impact factor: 5.075

2.  Combined endoscopic and open inguinal dissection for malignant melanoma.

Authors:  Claus Schneider; Jens P Brodersen; Hubert Scheuerlein; Carsten Tamme; Hans Lippert; Ferdinand Köckerling
Journal:  Langenbecks Arch Surg       Date:  2003-03-11       Impact factor: 3.445

Review 3.  Neoadjuvant treatment for melanoma: current challenges and future perspectives.

Authors:  Yana G Najjar; John M Kirkwood
Journal:  Melanoma Manag       Date:  2016-05-25

4.  Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases.

Authors:  Charles M Balch; Jeffrey E Gershenwald; Seng-Jaw Soong; John F Thompson; Shouluan Ding; David R Byrd; Natale Cascinelli; Alistair J Cochran; Daniel G Coit; Alexander M Eggermont; Timothy Johnson; John M Kirkwood; Stanley P Leong; Kelly M McMasters; Martin C Mihm; Donald L Morton; Merrick I Ross; Vernon K Sondak
Journal:  J Clin Oncol       Date:  2010-04-05       Impact factor: 44.544

Review 5.  Primary Melanoma: from History to Actual Debates.

Authors:  Alessandro A E Testori; Stephanie A Blankenstein; Alexander C J van Akkooi
Journal:  Curr Oncol Rep       Date:  2019-12-19       Impact factor: 5.075

6.  Clinicopathological Features, Staging, and Current Approaches to Treatment in High-Risk Resectable Melanoma.

Authors:  Emily Z Keung; Jeffrey E Gershenwald
Journal:  J Natl Cancer Inst       Date:  2020-09-01       Impact factor: 13.506

7.  Stage III thick (>4.0 mm) lower extremity melanoma: is timing of lymph node involvement a prognostic factor?

Authors:  Krzysztof Herman; Wojciech M Wysocki; Piotr Skotnicki; Jacek Tabor; Elebieta Luczyńska; Andrzej L Komorowski
Journal:  World J Surg       Date:  2009-03       Impact factor: 3.352

8.  From melanocyte to metastatic malignant melanoma.

Authors:  Bizhan Bandarchi; Linglei Ma; Roya Navab; Arun Seth; Golnar Rasty
Journal:  Dermatol Res Pract       Date:  2010-08-11

9.  Melanoma biomarkers: Vox clamantis in deserto (Review).

Authors:  Mays Al-Shaer; Divya Gollapudi; Chris Papageorgio
Journal:  Oncol Lett       Date:  2010-05-01       Impact factor: 2.967

Review 10.  Staging of cutaneous melanoma.

Authors:  P Mohr; A M M Eggermont; A Hauschild; A Buzaid
Journal:  Ann Oncol       Date:  2009-08       Impact factor: 32.976

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.